CD274 and neoplasm: The classification of patients into those whose tumours have less than or greater than 50% PD‐L1 TPS has profound implications on patient management, and tumour heterogeneity and sampling error can potentially incorrectly render patients ineligible for immunotherapies if misclassified as less than 50% [2].